New publication reports 1-year phase II results for denovoSkin™ in reconstructive surgery

A new peer-reviewed publication reports 1-year results from a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial evaluating denovoSkin™ in reconstructive surgery in patients of all ages. The study evaluated denovoSkin™ against autologous split-thickness skin grafts (STSG) in 23 patients with full-thickness skin defects requiring planned elective reconstruction. According to the publication, denovoSkin™ demonstrated significantly better scar quality than STSG at 3 months, with benefits maintained at 12 months.